7.32 USD
+0.53 (+7.81%)
6.7056 USD
-0.61 (-8.39%)
Taking everything into account, INGN scores 3 out of 10 in our fundamental rating. INGN was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While INGN seems to be doing ok healthwise, there are quite some concerns on its profitability. INGN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year INGN has reported negative net income.
In the past year INGN has reported a negative cash flow from operations.
INGN had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: INGN reported negative operating cash flow in multiple years.
1.2 Ratios
INGN has a Return On Assets of -8.27%. This is in the better half of the industry: INGN outperforms 64.32% of its industry peers.
INGN has a Return On Equity of -12.87%. This is in the better half of the industry: INGN outperforms 65.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.27% | ||
| ROE | -12.87% | ||
| ROIC | N/A |
ROA(3y)-21.41%
ROA(5y)-13.35%
ROE(3y)-32.95%
ROE(5y)-20.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INGN's Gross Margin of 44.76% is on the low side compared to the rest of the industry. INGN is outperformed by 62.16% of its industry peers.
In the last couple of years the Gross Margin of INGN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for INGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.76% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.22%
GM growth 5Y-0.6%
2. Health
2.1 Basic Checks
INGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INGN has more shares outstanding
INGN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.60, we must say that INGN is in the distress zone and has some risk of bankruptcy.
INGN's Altman-Z score of 1.60 is in line compared to the rest of the industry. INGN outperforms 54.59% of its industry peers.
INGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.6 |
ROIC/WACCN/A
WACC9.79%
2.3 Liquidity
A Current Ratio of 3.14 indicates that INGN has no problem at all paying its short term obligations.
The Current ratio of INGN (3.14) is comparable to the rest of the industry.
INGN has a Quick Ratio of 2.75. This indicates that INGN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.75, INGN is doing good in the industry, outperforming 63.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.22% over the past year.
Looking at the last year, INGN shows a small growth in Revenue. The Revenue has grown by 4.68% in the last year.
Measured over the past years, INGN shows a decrease in Revenue. The Revenue has been decreasing by -1.49% on average per year.
EPS 1Y (TTM)58.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
Revenue 1Y (TTM)4.68%
Revenue growth 3Y-2.12%
Revenue growth 5Y-1.49%
Sales Q2Q%4%
3.2 Future
INGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.49% yearly.
INGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.67% yearly.
EPS Next Y36.25%
EPS Next 2Y23.43%
EPS Next 3Y16.49%
EPS Next 5YN/A
Revenue Next Year7.88%
Revenue Next 2Y8.11%
Revenue Next 3Y6.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for INGN. In the last year negative earnings were reported.
Also next year INGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INGN's earnings are expected to grow with 16.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.43%
EPS Next 3Y16.49%
5. Dividend
5.1 Amount
INGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.32
+0.53 (+7.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners72.63%
Inst Owner Change0%
Ins Owners2.18%
Ins Owner Change1.51%
Market Cap198.74M
Revenue(TTM)347.03M
Net Income(TTM)-25.38M
Analysts82.5
Price Target13.26 (81.15%)
Short Float %3.21%
Short Ratio4.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.46%
Min EPS beat(2)42.07%
Max EPS beat(2)44.85%
EPS beat(4)4
Avg EPS beat(4)42.91%
Min EPS beat(4)33.97%
Max EPS beat(4)50.73%
EPS beat(8)7
Avg EPS beat(8)27.49%
EPS beat(12)9
Avg EPS beat(12)24.7%
EPS beat(16)11
Avg EPS beat(16)18.95%
Revenue beat(2)0
Avg Revenue beat(2)-0.95%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)-0.15%
Revenue beat(4)2
Avg Revenue beat(4)1.43%
Min Revenue beat(4)-1.76%
Max Revenue beat(4)6.23%
Revenue beat(8)5
Avg Revenue beat(8)1.9%
Revenue beat(12)5
Avg Revenue beat(12)-0.4%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.17%
EPS NY rev (1m)0%
EPS NY rev (3m)1.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.57 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.01 | ||
| P/tB | 1.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS12.78
BVpS7.26
TBVpS5.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.27% | ||
| ROE | -12.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.76% | ||
| FCFM | N/A |
ROA(3y)-21.41%
ROA(5y)-13.35%
ROE(3y)-32.95%
ROE(5y)-20.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.22%
GM growth 5Y-0.6%
F-Score6
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 53.85% | ||
| Cap/Sales | 3.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | 1.6 |
F-Score6
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)106.82%
Cap/Depr(5y)105.29%
Cap/Sales(3y)6.42%
Cap/Sales(5y)6.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
EPS Next Y36.25%
EPS Next 2Y23.43%
EPS Next 3Y16.49%
EPS Next 5YN/A
Revenue 1Y (TTM)4.68%
Revenue growth 3Y-2.12%
Revenue growth 5Y-1.49%
Sales Q2Q%4%
Revenue Next Year7.88%
Revenue Next 2Y8.11%
Revenue Next 3Y6.67%
Revenue Next 5YN/A
EBIT growth 1Y48.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.09%
EBIT Next 3Y30.49%
EBIT Next 5YN/A
FCF growth 1Y43.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.64%
OCF growth 3Y-36.98%
OCF growth 5Y-31.97%
INOGEN INC / INGN FAQ
What is the fundamental rating for INGN stock?
ChartMill assigns a fundamental rating of 3 / 10 to INGN.
What is the valuation status for INGN stock?
ChartMill assigns a valuation rating of 0 / 10 to INOGEN INC (INGN). This can be considered as Overvalued.
How profitable is INOGEN INC (INGN) stock?
INOGEN INC (INGN) has a profitability rating of 2 / 10.
How financially healthy is INOGEN INC?
The financial health rating of INOGEN INC (INGN) is 6 / 10.